Literature DB >> 17918768

Design, synthesis and evaluation of peptide inhibitors of Mycobacterium tuberculosis ribonucleotide reductase.

Johanna Nurbo1, Annette K Roos, Daniel Muthas, Erik Wahlström, Daniel J Ericsson, Torbjörn Lundstedt, Torsten Unge, Anders Karlén.   

Abstract

Mycobacterium tuberculosis ribonucleotide reductase (RNR) is a potential target for new antitubercular drugs. Herein we describe the synthesis and evaluation of peptide inhibitors of RNR derived from the C-terminus of the small subunit of M. tuberculosis RNR. An N-terminal truncation, an alanine scan and a novel statistical molecular design (SMD) approach based on the heptapeptide Ac-Glu-Asp-Asp-Asp-Trp-Asp-Phe-OH were applied in this study. The alanine scan showed that Trp5 and Phe7 were important for inhibitory potency. A quantitative structure relationship (QSAR) model was developed based on the synthesized peptides which showed that a negative charge in positions 2, 3, and 6 is beneficial for inhibitory potency. Finally, in position 5 the model coefficients indicate that there is room for a larger side chain, as compared to Trp5.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17918768     DOI: 10.1002/psc.906

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  9 in total

1.  Discovery of antimicrobial ribonucleotide reductase inhibitors by screening in microwell format.

Authors:  Fredrik Tholander; Britt-Marie Sjöberg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  Extensions to amino acid description.

Authors:  Johan Gottfries; Lennart Eriksson
Journal:  Mol Divers       Date:  2009-11-25       Impact factor: 2.943

3.  The class Ib ribonucleotide reductase from Mycobacterium tuberculosis has two active R2F subunits.

Authors:  Marta Hammerstad; Asmund K Røhr; Niels H Andersen; Astrid Gräslund; Martin Högbom; K Kristoffer Andersson
Journal:  J Biol Inorg Chem       Date:  2014-03-02       Impact factor: 3.358

4.  Function and regulation of class I ribonucleotide reductase-encoding genes in mycobacteria.

Authors:  Mohube B Mowa; Digby F Warner; Gilla Kaplan; Bavesh D Kana; Valerie Mizrahi
Journal:  J Bacteriol       Date:  2008-11-21       Impact factor: 3.490

5.  Design of glycopeptides used to investigate class II MHC binding and T-cell responses associated with autoimmune arthritis.

Authors:  Ida E Andersson; C David Andersson; Tsvetelina Batsalova; Balik Dzhambazov; Rikard Holmdahl; Jan Kihlberg; Anna Linusson
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

6.  Synthesis and Biological Evaluation of Thiosemicarbazide Derivatives Endowed with High Activity toward Mycobacterium Bovis.

Authors:  Soroush Sardari; Samaneh Feizi; Ali Hossein Rezayan; Parisa Azerang; Seyyed Mohammad Shahcheragh; Ghazaleh Ghavami; Azizollah Habibi
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

Review 7.  Computer-Aided Design of Antimicrobial Peptides: Are We Generating Effective Drug Candidates?

Authors:  Marlon H Cardoso; Raquel Q Orozco; Samilla B Rezende; Gisele Rodrigues; Karen G N Oshiro; Elizabete S Cândido; Octávio L Franco
Journal:  Front Microbiol       Date:  2020-01-22       Impact factor: 5.640

8.  Synthesis of Novel Fluorene Bisamide Derivatives via Ugi Reaction and Evaluation their Biological Activity against Mycobacterium species.

Authors:  Ali Hossein Rezayan; Safoura Hariri; Parisa Azerang; Ghazaleh Ghavami; Isabel Portugal; Soroush Sardari
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

9.  First genome sequencing and comparative analyses of Corynebacterium pseudotuberculosis strains from Mexico.

Authors:  Doglas Parise; Mariana T D Parise; Marcus V C Viana; Adrian V Muñoz-Bucio; Yazmin A Cortés-Pérez; Beatriz Arellano-Reynoso; Efrén Díaz-Aparicio; Fernanda A Dorella; Felipe L Pereira; Alex F Carvalho; Henrique C P Figueiredo; Preetam Ghosh; Debmalya Barh; Anne C P Gomide; Vasco A C Azevedo
Journal:  Stand Genomic Sci       Date:  2018-10-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.